Development of Small Molecules Activating TRAIL Apoptosis Pathway for Cancer Therapies
References
[1]
E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N., Fiore and B. Williamson, “An Endotoxin-Induced Serum Factor that Causes Necrosis of Tumors,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 72, No. 9, 1975, pp. 3666-3670.
http://dx.doi.org/10.1073/pnas.72.9.3666
[2]
A. C Bellail, L. Qi, P. Mulligan, V. Chhabra and C. Hao, “TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges,” Reviews on Recent Clinical Trials, Vol. 4, No. 1, 2009, pp. 34-41.
http://dx.doi.org/10.2174/157488709787047530
[3]
K. J. Tracey, B. Beutler, S. F. Lowry, J. Merryweather, S Wolpe, I. W. Milsark, R. J. Hariri, T. J. Fahey 3rd, A. Zentella, J. D. Albert, et al., “Shock and Tissue Injury Induced by Recombinant Human Cachectin,” Science, Vol. 234, No. 4775, 1986, pp. 470-474.
http://dx.doi.org/10.1126/science.3764421
[4]
J. Ogasawara, R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata, “Lethal Effect of the Anti-Fas Antibody in Mice,” Nature, Vol. 364, No. 6440, 1993, pp. 806-809.
http://dx.doi.org/10.1038/364806a0
[5]
S. R. Wiley, K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith, et al., “Identification and Characterization of a New Member of the TNF Family That Induces Apoptosis,” Immunity, Vol. 3, No. 6, 1995, pp. 673-682.
http://dx.doi.org/10.1016/1074-7613(95)90057-8
[6]
R. M. Pitti, S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore and A. Ashkenazi, “Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family,” The Journal of Biological Chemistry, Vol. 271, No. 22, 1996, pp. 12687-12690.
http://dx.doi.org/10.1074/jbc.271.22.12687
[7]
D. Lawrence, Z. Shahrokh, S. Marsters, K. Achilles, D. Shih, B. Mounho, K. Hillan, K. Totpal, L. DeForge, P. Schow, et al., “Differential Hepatocyte Toxicity of Recombinant Apo2L/TRAIL Versions,” Nature Medicine, Vol. 7, No. 4, 2001, pp. 383-385.
http://dx.doi.org/10.1038/86397
[8]
C. Hao, J. H. Song, B. Hsi, J. Lewis, D. K. Song, K. C. Petruk, D. L. Tyrrell and N. M. Kneteman, “TRAIL Inhibits Tumor Growth But Is Nontoxic to Human Hepatocytes in Chimeric Mice,” Cancer Research, Vol. 64, No. 23, 2004, pp. 8502-8506.
http://dx.doi.org/10.1158/0008-5472.CAN-04-2599
[9]
M. J. Smyth, K. Takeda, Y. Hayakawa, J. J. Peschon, M. R. van den Brink and H. Yagita, “Nature’s TRAIL—On a Path to Cancer Immunotherapy,” Immunity, Vol. 18, No. 1, 2003, pp. 1-6.
http://dx.doi.org/10.1016/S1074-7613(02)00502-2
[10]
S. S. Cha, M. S. Kim, Y. H. Choi, B. J. Sung, N. K. Shin, H. C. Shin, Y. C. Sung and B. H. Oh, “2.8 ? Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity,” Immunity, Vol. 11, No. 2, 1999, pp. 253-261.
http://dx.doi.org/10.1016/S1074-7613(00)80100-4
[11]
R. S. Herbst, S. G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P. J. O’Dwyer, M. S. Gordon, W. Novotny, M. A. Goldwasser, T. M. Tohnya, B. L. Lum, et al., “Phase I Dose-Escalation Study of Recombinant Human Apo2L/ TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients with Advanced Cancer,” Journal of Clinical Oncology, Vol. 28, No. 17, 2010, pp. 2839-2846.
http://dx.doi.org/10.1200/JCO.2009.25.1991
[12]
J. C. Soria, E. Smit, D. Khayat, B. Besse, X. Yang, C. P. Hsu, D. Reese, J. Wiezorek and F. Blackhall, “Phase 1b Study of Dulanermin (Recombinant Human Apo2L/ TRAIL) in Combination with Paclitaxel, Carboplatin, and Bevacizumab in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 28, No. 9, 2010, pp. 1527-1533.
http://dx.doi.org/10.1200/JCO.2009.25.4847
[13]
J. C. Soria, Z. Mark, P. Zatloukal, B. Szima, I. Albert, E. Juhasz, J. L. Pujol, J. Kozielski, N. Baker, D. Smethurst, et al., “Randomized Phase II Study of Dulanermin in Combination with Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Vol. 29, No. 33, 2011, pp. 4442-4451. http://dx.doi.org/10.1200/JCO.2011.37.2623
[14]
K. Ichikawa, W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J. D. Mountz, W. J. Koopman, R. P. Kimberly, et al., “Tumoricidal Activity of a Novel Anti-Human DR5 Monoclonal Antibody without Hepatocyte Cytotoxicity,” Nature Medicine, Vol. 7, No. 8, 2001, pp. 954-960. http://dx.doi.org/10.1038/91000
[15]
A. Yada, M. Yazawa, S. Ishida, H. Yoshida, K. Ichikawa, S. Kurakata and K. Fujiwara, “A Novel Humanized Anti-Human Death Receptor 5 Antibody CS-1008 Induces Apoptosis in Tumor Cells without Toxicity in Hepatocytes,” Annals of Oncology, Vol. 19, No. 6, 2008, pp. 1060-1067. http://dx.doi.org/10.1093/annonc/mdn015
[16]
A. Forero-Torres, J. Shah, T. Wood, J. Posey, R. Carlisle, C. Copigneaux, F. R. Luo, S. Wojtowicz-Praga, I. Percent, and M. Saleh, “Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5),” Cancer Biotherapy & Radiopharmaceuticals, Vol. 25, No. 1, 2010, pp. 13-19.
http://dx.doi.org/10.1089/cbr.2009.0673
[17]
R. C. Humphreys and W. Halpern, “Trail Receptors: Targets for Cancer Therapy,” Advances in Experimental Medicine and Biology, Vol. 615, 2008, pp. 127-158.
http://dx.doi.org/10.1007/978-1-4020-6554-5_7
[18]
A. W. Tolcher, M. Mita, N. J. Meropol, M. von Mehren, A. Patnaik, K. Padavic, M. Hill, T. Mays, T. McCoy, N. L. Fox, et al., “Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody with Agonist Activity to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor-1,” Journal of Clinical Oncology, Vol. 25, No. 28, 2007, pp. 1390-1395.
http://dx.doi.org/10.1200/JCO.2006.08.8898
[19]
R. Plummer, G. Attard, S. Pacey, L. Li, A. Razak, R. Perrett, M. Barrett, I. Judson, S. Kaye, N. L. Fox, et al., “Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers,” Clinical Cancer Research, Vol. 13, No. 20, 2007, pp. 6187-6194.
http://dx.doi.org/10.1158/1078-0432.CCR-07-0950
[20]
D. R. Camidge, R. S. Herbst, M. S. Gordon, S. G. Eckhardt, R. Kurzrock, B. Durbin, J. Ing, T. M. Tohnya, J. Sager, A. Ashkenazi, et al., “A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies,” Clinical Cancer Research, Vol. 16, No. 4, 2010, pp. 1256-1263.
http://dx.doi.org/10.1158/1078-0432.CCR-09-1267
[21]
F. A Greco, P. Bonomi, J. Crawford, K. Kelly, Y. Oh, W. Halpern, L. Lo, G. Gallant and J. Klein, “Phase 2 Study of Mapatumumab, a Fully Human Agonistic Monoclonal Antibody Which Targets and Activates the TRAIL Receptor-1, in Patients with Advanced Non-Small Cell Lung Cancer,” Lung Cancer, Vol. 61, No. 1, 2008, pp. 82-90.
http://dx.doi.org/10.1016/j.lungcan.2007.12.011
[22]
T. Trarbach, M. Moehler, V. Heinemann, C. H. Kohne, M. Przyborek, C. Schulz, V. Sneller, G. Gallant and S. Kanzler, “Phase II Trial of Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets and Activates the Tumour Necrosis Factor Apoptosis-Inducing Ligand Receptor-1 (TRAIL-R1), in Patients with Refractory Colorectal Cancer,” British Journal of Cancer, Vol. 102, No. 3, 2010, pp. 506-512.
http://dx.doi.org/10.1038/sj.bjc.6605507
[23]
J. E. Allen, G. Krigsfeld, P. A. Mayes, L. Patel, D. T. Dicker, A. S. Patel, N. G. Dolloff, E. Messaris, K. A. Scata, W. Wang, et al., “Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects,” Science Translational Medicine, Vol. 5, No. 171, 2013, p.171ra17.
http://dx.doi.org/10.1126/scitranslmed.3004828
[24]
G. Wang, X. Wang, H. Yu, S. Wei, N. Williams, D. L. Holmes, R. Halfmann, J. Naidoo, L. Wang, L. Li, et al., “Small-Molecule Activation of the TRAIL Receptor DR5 in Human Cancer Cells,” Nature Chemical Biology, Vol. 9, 2013, pp. 84-89.
http://dx.doi.org/10.1038/nchembio.1153
